Literature DB >> 1716140

The influence of Org 10172, a low molecular weight heparinoid, on antipyrine metabolism and the effect of enzyme induction on the response to Org 10172.

A De Boer1, J C Stiekema, M Danhof, D D Breimer.   

Abstract

1. We have investigated the effect of repeated s.c. Org 10172 (a low molecular weight heparinoid; Lomoparan) treatment (1000 anti-Xa units twice daily for 5 days) on antipyrine (500 mg orally) metabolism, and the effect of enzyme induction by pentobarbitone (100 mg for 12 days) on the pharmacokinetics and pharmacodynamics of Org 10172 following an intravenous bolus injection of 3250 anti-Xa units. 2. Org 10172 treatment caused a small increase in the formation rates of all antipyrine metabolites (P less than 0.05), while the overall kinetics of antipyrine did not change significantly. 3. Oxidative enzyme induction by pentobarbitone, as demonstrated by an increased clearance of antipyrine, was associated with an increase in the area under the anti-thrombin activity vs time curve (P less than 0.05). No influence was seen on the kinetics of plasma anti-Xa and thrombin generation inhibiting (TGI) activity. 4. The pharmacodynamics of Org 10172, as determined by clotting tests, was not influenced by enzyme induction. 5. The clinical relevance of these observations is likely to be limited.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1716140      PMCID: PMC1368488          DOI: 10.1111/j.1365-2125.1991.tb05608.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

1.  The antipyrine test in clinical pharmacology: conceptions and misconceptions.

Authors:  E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

2.  What is the best plasmatic activity which could be correlated with the antithrombotic effect of heparin and a low molecular weight heparin fragment?

Authors:  C Doutremepuich; T Castrioto; O De Seze; F Pereira; F Doutremepuich; M C Anne; F Toulemonde
Journal:  Thromb Res       Date:  1987-10-15       Impact factor: 3.944

3.  Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III.

Authors:  A N Teien; M Lie
Journal:  Thromb Res       Date:  1977-03       Impact factor: 3.944

4.  ELSMOS--an extended least squares modelling system in FORTRAN IV for mini- or micro-computer implementation.

Authors:  R J Francis
Journal:  Comput Programs Biomed       Date:  1984 Feb-Apr

5.  Differential effects of enzyme induction on antipyrine metabolite formation.

Authors:  M Danhof; R M Verbeek; C J van Boxtel; J K Boeijinga; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1982-03       Impact factor: 4.335

6.  Studies of the different metabolic pathways of antipyrine in man. Oral versus i.v. administration and the influence of urinary collection time.

Authors:  M Danhof; A van Zuilen; J K Boeijinga; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

7.  Interaction of phenobarbital with propranolol in the dog. 3. Beta blockade.

Authors:  S A Bai; F P Abramson
Journal:  J Pharmacol Exp Ther       Date:  1983-01       Impact factor: 4.030

8.  Heparan sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways.

Authors:  F A Ofosu; G J Modi; L M Smith; A L Cerskus; J Hirsh; M A Blajchman
Journal:  Blood       Date:  1984-09       Impact factor: 22.113

9.  Time courses of the antithrombotic effects, bleeding enhancing effects and interactions with factors Xa and thrombin after administration of low molecular weight heparinoid Org 10172 or heparin to rats.

Authors:  P M Hobbelen; G M Vogel; D G Meuleman
Journal:  Thromb Res       Date:  1987-12-01       Impact factor: 3.944

10.  A novel anti-thrombotic heparinoid (Org 10172) devoid of bleeding inducing capacity: a survey of its pharmacological properties in experimental animal models.

Authors:  D G Meuleman; P M Hobbelen; G van Dedem; H C Moelker
Journal:  Thromb Res       Date:  1982-08-01       Impact factor: 3.944

View more
  2 in total

Review 1.  Danaparoid: a review of its use in thromboembolic and coagulation disorders.

Authors:  Tim Ibbotson; Caroline M Perry
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia.

Authors:  M I Wilde; A Markham
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.